70 results
6-K
EX-4.2
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding … other cases, the fair market value of an Ordinary Share as determined by an independent appraiser selected in good faith by the Holders of a majority
6-K
EX-1.1
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee … ) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority
6-K
EX-4.3
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding … other cases, the fair market value of an Ordinary Share as determined by an independent appraiser selected in good faith by the Holders of a majority
6-K
EX-4.1
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding … other cases, the fair market value of an Ordinary Share as determined by an independent appraiser selected in good faith by the Holders of a majority
6-K
EX-4.4
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company … of an Ordinary Share as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities
6-K
EX-4.5
mskvbfc9q68lbcmsxzv
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
424B5
ncjq15sj
29 May 24
Prospectus supplement for primary offering
4:15pm
6-K
EX-99.1
dxlrr
17 Jan 24
Report of Foreign Private Issuer
8:02am
6-K
hmhczai ne42
2 Nov 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
1uvow88dwf8c
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
424B5
3kkroowfxso594a4
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
neczj0tyw df
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
6-K
EX-99.1
fv575b765ibw1
29 Apr 22
Report of Foreign Private Issuer
8:15am
F-3
sqln5gzg
29 Apr 22
Shelf registration (foreign)
8:14am